LM-108
- Generic Name
- LM-108
LaNova Medicines Initiates Phase 1 Trial of LM-299, Anti-PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
• LaNova Medicines has begun a Phase 1 clinical trial in China for LM-299, a bispecific antibody targeting PD-1 and VEGF, in patients with advanced solid tumors.
• Preclinical studies of LM-299 demonstrated strong inhibition of tumor growth and a favorable safety profile, supporting its advancement into human trials.
• LaNova anticipates submitting an Investigational New Drug (IND) application to the FDA for LM-299 in the United States in the second half of 2024.
• The company's recent $42 million Series C1 financing will support the clinical development of LM-299, along with other pipeline candidates like LM-302 and LM-108.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath